Axsome released their first quarter financial results on Monday May 8th. Just a few highlights from the just completed impressive quarter, are below.
- Auvelity for MDD sales totaled $15.7 million for the quarter
- Sunosi for narcolepsy sales totaled $12.9 million for the quarter
- $246 million in cash on hand, end of quarter
- AXS-12 clinical trial for cataplexy, to read out in the second quarter
Axsome's share price has been moving steadily higher the past couple weeks. Below is a monthly chart of AXSM stock, which has just closed at it's highest level seen in the past two years. Thank you for reading.
